Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.
about
The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patientsRespiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era.Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovirHIV and chronic obstructive pulmonary disease: is it worse and why?Monocytes expand with immune dysregulation and is associated with insulin resistance in older individuals with chronic HIV.Association of antiretroviral therapy with fibrinogen levels in HIV-infection.Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population.Coronary heart disease in HIV-infected patients.Portal vein thrombosis in a patient with HIV treated with a protease inhibitor-containing regimen.Toxic metabolic syndrome associated with HAART.Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.Human immunodeficiency virus infection and acute deep vein thromboses.Risk of Venous Thromboembolism in Patients Infected with HIV: A Cohort Study.Is HIV-1 infection associated with endothelial dysfunction in a population of African ancestry in South Africa?Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era.Review: Viral infections and mechanisms of thrombosis and bleeding.Pulmonary Embolism Mimicking Pneumonia in a HIV Patient.Impact of short-term antiretroviral therapy (START) on some fibrinolytic markers in HIV-infected Nigerian adults: preliminary findings from the START study.A comparison of the predicted risk for cardiovascular disease between HIV-infected and uninfected persons in Korea.Acute myocardial infarction and rescue percutaneous transluminal coronary angioplasty in a young HIV-infected patient.Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series.Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.HIV as a Cause of Immune Activation and Immunosenescence.The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy
P2860
Q26862601-C1721EAB-4847-46A4-8213-903506D6D5DEQ33484755-E463579C-B04E-49F5-935F-D54AA328C2B2Q33812049-50FCFA04-DBE6-4E57-91A7-51746C92480FQ35095058-28CD0B04-39B7-486B-8454-06625FE980DEQ35108968-5F3B53D5-4D68-46FE-A5DF-52B339568E63Q35166181-32DAA722-9098-4996-BDA6-D63498922634Q36070094-FBB30E95-01CC-4E7C-91E5-B69C963E334BQ36223870-9B9BF7F9-F954-4AA7-84B8-F810B28A16C2Q36468070-8114D7D7-AFD1-47B8-8BB1-6C55901ED950Q36544924-988FA168-39C5-4AE9-AECD-41FAF6FB722CQ36903976-0F3B83BD-1921-477C-B73D-56D4578A4844Q36951527-866866FB-A951-4046-8352-0DD9497C8B02Q37007898-7BE0A2A3-F7B7-4E79-90EB-BE95658D22ECQ37042012-ACC551B9-457B-44B3-8571-CEFA3CC5A7D0Q37265511-83CAC4C8-5E68-4B78-BE2F-41BF0AC65C1AQ38038832-D410684C-91B8-48CB-BC8F-4437D533A06EQ40355131-4074CAC5-3C3C-4139-8E59-77886A9745BBQ41836230-0C834E0E-6529-47B1-84CE-B04C542C3569Q42275051-63D25500-5E67-4042-85C4-AD5B5AA8A839Q43547451-5D6F9C42-5411-421E-9280-362A73A7CBB5Q45108757-9907CEFC-9DBE-42F2-9885-9519E4A47FFDQ46675079-6A603346-EE2A-4F62-A366-AE9E39A258F7Q47151081-3B8CD41A-D140-478E-8161-7B5696647BCAQ51943315-08A84A88-7AB6-4E55-A3E9-0D33736E5308Q57079976-69EC71A6-E2A7-4927-8201-67D4911428FF
P2860
Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Hypofibrinolytic state in HIV- ...... active antiretroviral therapy.
@en
Hypofibrinolytic state in HIV- ...... active antiretroviral therapy.
@nl
type
label
Hypofibrinolytic state in HIV- ...... active antiretroviral therapy.
@en
Hypofibrinolytic state in HIV- ...... active antiretroviral therapy.
@nl
prefLabel
Hypofibrinolytic state in HIV- ...... active antiretroviral therapy.
@en
Hypofibrinolytic state in HIV- ...... active antiretroviral therapy.
@nl
P2093
P1476
Hypofibrinolytic state in HIV- ...... active antiretroviral therapy.
@en
P2093
Eric Sandström
Göran Bratt
Håkan Bylund
Kristina Koppel
P304
P356
10.1097/00042560-200204150-00003
P407
P50
P577
2002-04-01T00:00:00Z